A tale of two vaccines: AstraZeneca's shot still a blockbuster, but Pfizer sales are on another level
With AstraZeneca’s second quarter earnings call Thursday morning came updated sales numbers for its Covid-19 vaccine — and compared to the big mRNA players, the numbers pale in comparison.
The British-Swedish drugmaker reported its Covid-19 jab has raked in about $1.17 billion globally in the first half, including $894 million in the second quarter alone. Pfizer, meanwhile, has seen skyrocketing growth of its vaccine with $3.5 billion in sales in the first quarter and another $7.8 billion in the second quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.